Comparison of montelukast and intranasal antihistamine in allergic rhinitis treatment

Comparative study of montelukast and intranasal antihistamine in treatment of moderate to severe allergic rhinitis in Shiraz Emam Reza Clinic in 2020

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200906048642N1

Enrollment

Registered

2020-09-16

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis. Allergic rhinitis, unspecified

Interventions

Intervention 1: Intervention group: Treatment group with Montelukast and Budesonide nasal spray in this group consisting of 22 patients.Montelukast Dr.Abidi factory with a dose of 5 mg per day to pati

Eligibility

Sex/Gender

All

Age

6 Years to 50 Years

Inclusion criteria

Inclusion criteria: Moderate to severe allergic rhinitis Seasonal and perennial allergic rhinitis

Exclusion criteria

Exclusion criteria: Mild or intermittent allergic rhinitis Chronic diseases under treatment(chronic kidney disease,hypertension,diabetes mellitus) History of drug reaction Immunotherapy Infectious rhinosinusitis

Design outcomes

Primary

Measure	Time frame
Quality of life via SNOT22. Timepoint: Monthly up to 3 months. Method of measurement: SNOT22 questionnaire.	—

Secondary

Measure	Time frame
Patient symptoms. Timepoint: Monthly to 3 months. Method of measurement: SNOT22 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Mortazavi Far

Shiraz University of Medical Sciences

nasrinmortazavi@yahoo.com+98 71 3647 4334

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026